The Sahajanand Medical Technologies IPO was subscribed 1.34 times by 11:30 am on October 19. The Rs 475.48-crore issue got strong demand from non-institutional and retail investors. Shares also showed an 8 percent premium in the grey market. The company earlier raised funds from eight institutional investors through an anchor book.
Market Mastery
Webinar by Vishal Malkan
Find the weak links
in your portfolio by Vishal Malkan
The initial public offering (IPO) of Mumbai-headquartered cardiovascular device maker Sahajanand Medical Technologies was subscribed 1.34 times by 11:30 am on October 19, as per the NSE data.
The Rs 475.48-crore IPO received bids for 1,30,39,277 shares against 97,50,482 shares on offer. The non-institutional investors led the demand with 1.8 times subscription, followed by retail investors with 1.32 times subscription.
In the grey market, the Sahajanand Medical Technologies shares were commanding a premium of 8 percent on the morning of October 19, as per InvestorGain. However, grey market premiums are unofficial indicators based on speculative trading and do not guarantee listing gains.
Read Also: Zetwerk IPO subscribed 47% so far on last day of bidding; GMP drops to 3%
Ahead of the issue opening, the company mobilised 140.06 crore through anchor investors. Sahajanand Medical Technologies allotted 40.71 lakh equity shares to eight institutional investors through the anchor book on October 14 at the upper end of the price band.
Of the total allocation, 30.25 lakh shares, worth approximately Rs 104 crore, were allotted to five domestic mutual fund houses: Nippon Life India, DSP Mutual Fund, WhiteOak Capital, Invesco India, and UTI AMC. These investors participated through a total of seven schemes.
Allianz Global Investors Fund, Tata AIA Life Insurance Company, and Natixis International Funds were among the other participants in the anchor book.
Check IPO News Here
The company seeks to raise up to Rs 475.48 crore entirely through an offer for sale (OFS) of 1.38 crore equity shares.
Sahajanand Medical Technologies develops Class III and Class C/D medical devices, primarily focusing on vascular intervention (VI) products, including coronary stents and coronary balloons, and structural heart (SH) products, including transcatheter aortic valve implantation (TAVI) devices and occluders. Its product portfolio also includes renal stents under its own brand and peripheral drug-coated balloons (DCBs).
Motilal Oswal Investment Advisors, Avendus Capital, HSBC Securities and Capital Markets (India), and Nuvama Wealth Management are acting as the merchant bankers to the IPO.